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Nudges and Norms in Multidistrict Litigation: A 
Response to Engstrom 
Elizabeth Chamblee Burch 
abstract.  On paper, the Federal Rules of Civil Procedure apply equally to billion-dollar opi-
oid allegations and claims for $75,000.01. In practice, however, judges and attorneys in high-stakes 
multidistrict proceedings like those over opioids have invented a smattering of procedures you will 
never find in the Federal Rules: plaintiff fact sheets, short-form complaints, science days, bell-
wether trials, census orders, inactive dockets, and Lone Pine orders, to name but a few. In a world 
where settlement is the prevailing currency, new norms take root. But as these norms blossom, the 
stabilizing features of the federal rules—balance, predictability, and structural protections—can 
wither. As safeguards atrophy and transferee judges actively nudge the parties to settle, the deals 
that emerge may reflect the scars of creative pruning, not the suit’s merits. 
 This Essay responds to Nora Engstrom’s article, The Lessons of Lone Pine, by introducing em-
pirical data on her target (Lone Pine orders) and her remedy (plaintiff fact sheets). Examining 
these two innovations in the lifecycle of products-liability multidistrict litigation illustrates that 
norms can undermine a key aim of the Federal Rules: achieving procedural parity, where discovery 
burdens and the risks of erroneous decisions fall equally on both parties. Although procedural 
design choices should respond to case-management demands, both shortcuts can impact plaintiffs 
more harshly, upending protections for those who need them most. 
introduction 
The world of mass-tort multidistrict litigation that Nora Engstrom describes 
in her recent Yale Law Journal Article, The Lessons of Lone Pine, is foreign to most 
lawyers.1 These proceedings command not only their own lingo, like Lone Pine 
orders, census orders, and fact sheets, but also their own bespoke procedures, 
 
1. See Nora Freeman Engstrom, The Lessons of Lone Pine, 129 YALE L.J. 2 (2019). 
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which an elite cadre of federal judges invoke to wrangle cases into settlement.2 
That means that a key assumption behind the Federal Rules of Civil Procedure—
that “a litigant can walk into any federal courtroom in the country and know that 
the same procedures will apply to her case”—does not ring true.3 For the unini-
tiated, Lone Pine orders require mass-tort plaintiffs to prove that the defendant’s 
product or device caused their injuries with an expert report, such as one from a 
surgeon or physician.4 As a judicial concoction, Lone Pine orders are the pluots 
of mass torts, grafting together snippets of federal rules while ignoring their pro-
cedural protections.5 
In stark contrast to most existing literature lauding Lone Pine orders, Eng-
strom deftly exposes their deep flaws: Lone Pine orders circumvent jury trials, 
little precedent exists to guide them, and, as a case-management tool under Rule 
16, they are afforded an abuse-of-discretion standard on appeal rather than the 
stricter de novo standard used for summary judgment.6 Put simply, Lone Pine 
orders bypass institutional constraints and are out of step with existing proce-
dural rules. Like summary-judgment motions, they demand substantive support 
for claims, but they short-circuit Rule 56’s procedural protections and clear bur-
dens of proof. And like Rule 11 sanctions, they hope to siphon off frivolous 
claims, but they demand that plaintiffs provide expert reports and prima facie 
evidence of their injury, whereas Rule 11 merely requires that lawyers certify that 
 
2. Some transferee judges in federal multidistrict proceedings have begun to issue census orders 
(or registration orders) at the settling parties’ request. These require all attorneys to register 
their clients’ state and federal claims, whether filed or unfiled, so that the settling defendant 
can use that number as the denominator for calculating compliance with a settlement’s walk-
away percentage. (They are, of course dubious, because federal jurisdiction attaches to claims, 
not lawyers.) I explore walkaway provisions in note 31, infra, and the accompanying text. Fact 
sheets are court-ordered forms that sometimes act as a substitute for more formal discovery 
tools like interrogatories, requests to produce documents, and depositions. I take a closer look 
at plaintiff fact sheets in Part II, infra, but judges have used fact sheets for both plaintiffs and 
defendants in multidistrict proceedings. 
3. Abbe R. Gluck, Unorthodox Civil Procedure: Modern Multidistrict Litigation’s Place in the Text-
book Understandings of Procedure, 165 U. PA. L. REV. 1669, 1687 (2017). As Engstrom explains, 
Lone Pine orders have been used in state courts, too, but my focus here is on federal cases. 
4. To recover in tort, plaintiffs must prove that the defendant’s product, device, or action proxi-
mately caused her injuries. The expert report by a doctor or specialist, for example, thus helps 
plaintiffs link their injury to the defendant’s action or inaction and prove causation by a pre-
ponderance of the evidence. 
5. For other examples, see Pamela K. Bookman & David L. Noll, Ad Hoc Procedure, 92 N.Y.U. L. 
REV. 767 (2017); Linda S. Mullenix, Dubious Doctrines: The Quasi-Class Action, 80 U. CIN. L. 
REV. 389 (2011). 
6. See Engstrom, supra note 1, at 36-52. 
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support exists or is likely to exist after discovery.7 Finally, like discovery sanctions 
under Rule 37, Lone Pine orders dismiss noncompliant cases, but contrary to this 
Rule they do so as a first step rather than a last resort. 
Why do judges use them then? Some judges and defense lawyers claim that 
Lone Pine orders “represent salvation from the huddled masses of meritless 
plaintiffs’ claims lying in wait for eventual settlement checks.”8 With that in 
mind, Engstrom suggests a balance: judges should use Lone Pine orders spar-
ingly and “only when (1) procedures explicitly sanctioned by rule or statute are 
unavailable or are patently insufficient, and (2) substantial evidence casts doubt 
upon plaintiffs’ entitlement to relief and/or the plaintiffs have displayed a 
marked and unjustifiable lack of diligence.”9 In lieu of Lone Pine orders, Eng-
strom contends that judges should winnow claims by requiring plaintiff fact 
sheets and disincentivizing noncompliance, “with a first step being that . . . non-
compliant plaintiffs will face entry of a Lone Pine order, and those who fail to 
comply with that order will see their claims dismissed with prejudice.”10 
Engstrom’s article is a tour-de-force on Lone Pine orders and should be re-
quired reading for every transferee judge who handles a mass-tort multidistrict 
litigation (MDL). Her dataset includes a wide array of Lone Pine orders used in 
both state and federal courts, many of which were issued during discovery and 
before a proceeding settled.11 
Volume-wise, state courts handle more mass-tort cases than federal courts 
do. But once the Judicial Panel on Multidistrict Litigation (the Panel) centralizes 
federal cases before a transferee judge, that judge and the attorneys she selects to 
spearhead the MDL proceeding tend to be in the driver’s seat when it comes to 
negotiating a global settlement. As Part I explores, global deals aim to include all 
plaintiffs, regardless of whether they sued in state or federal court.  
Part I thus narrows the scope of our inquiry, shifting away from how all state 
and federal courts use Lone Pine orders to how transferee judges employ them in 
products-liability MDLs. Products liability encompasses the largest and thorni-
est mass torts, like asbestos and pelvic mesh, which tend to demand heavy-
 
7. ELIZABETH CHAMBLEE BURCH, MASS TORT DEALS: BACKROOM BARGAINING IN MULTIDISTRICT 
LITIGATION 129-30 (2019). 
8. Engstrom, supra note 1, at 22 (citing Rachel B. Weil, Knee Implant MDL Judge Enters Aggressive 
Lone Pine Order, DRUG & DEVICE L. (June 23, 2016), https://www.druganddevicelawblog 
.com/2016/06/10720.html [https://perma.cc/JY86-GJPJ]. 
9. Engstrom, supra note 1, at 12. 
10. Id. at 60. 
11. See Nora Freeman Engstrom & Amos Espeland, Lone Pine Orders: A Critical Examination and 
Empirical Analysis (unpublished paper on file with author). 
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handed case management.12 Corralling dispersed plaintiffs into a single settle-
ment framework takes some doing, and ethics rules can take a backseat to closure 
goals.13 Looking at the lifecycle of mass torts in that context shows that Lone Pine 
orders appear almost exclusively post-settlement—not as pre-settlement sieves, 
but as an additional means to urge non-settling plaintiffs to settle.14 
Repositioning Lone Pine orders as settlement nudges means that they should 
fail the first prong of Engstrom’s test, for tried-and-true procedures already exist 
to resolve cases without them. When plaintiffs refuse a settlement offer, nothing 
about the status quo should change. Non-settling plaintiffs should be able to 
continue their path toward trial. If they have not completed discovery, then dis-
covery should continue. If they don’t respond to discovery requests, then the 
court could consider whether to issue Rule 37 sanctions and dismiss the case. 
Alternatively, if pretrial matters have concluded, plaintiffs’ cases should be re-
manded to their original court for trial as the MDL statute contemplates.15 
Part II explores Engstrom’s proposed solution—using plaintiff fact sheets in 
lieu of Lone Pine orders. Unlike Lone Pine orders, fact sheets do appear routinely 
before a global settlement. But, as yet another ad hoc invention that substitutes 
for formal discovery rules, they fall prey to some of the same criticisms that Eng-
strom levels at Lone Pine orders. 
 
12. I focus on product-liability MDLs because that category captures the personal-injury mass 
torts that tend to include the most plaintiffs. Historically, products-liability proceedings have 
constituted the largest segment of MDLs, constituting well over one-third of the Panel’s 
docket. And looking at the number of actions contained in each proceeding shows that prod-
ucts-liability cases comprise around 90% of pending actions. Elizabeth Chamblee Burch & 
Margaret S. Williams, Repeat Players in Multidistrict Litigation: The Social Network, 102 COR-
NELL L. REV. 1445, 1460-63 (2017). Transvaginal mesh, or “pelvic mesh” as it has become 
known, is a product used to treat pelvic organ prolapse, but the mesh can pierce women’s 
internal organs and wreak havoc on their bodies. Even revision surgeries may not be success-
ful because the mesh can splinter internally. Most pelvic mesh has now been pulled from the 
market. 
13. For more on these practices, see BURCH, supra note 7, at 44-54, 60-62. 
14. Erin Marie Day, Lawyers Debate Value of ‘Lone Pine’ Orders, LAW360 (July 24, 2008), 
https://www.law360.com/articles/63725/lawyers-debate-value-of-lone-pine-orders 
[https://perma.cc/WLF2-C92U] (quoting Chris Seeger on Lone Pine orders as saying, “Many 
judges won’t enter them at all, but of those that do, it’s always near the end of the case”). 
Engstrom notes that 38% of the courts in her dataset entered Lone Pine orders early in the 
litigation and only 24% used them later in the proceeding. See id. at 14. 
15. 28 U.S.C. § 1407(a) (2018) (“Each action so transferred shall be remanded by the panel at or 
before the conclusion of such pretrial proceedings to the district from which it was trans-
ferred . . . .”). 
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i .  lone pine  orders as settlement nudges 
As Engstrom points out, there is widespread agreement that not all mass-
tort plaintiffs have valid claims, even though no firm data exists on the topic.16 
But if plaintiffs’ attorneys file dubious claims, it’s with the hope of getting some 
small payout from a settlement grid—a volume game that they would lose if they 
withheld those claims from a settlement program.17 So, if transferee judges issue 
Lone Pine orders after lead attorneys negotiate a settlement, those orders are un-
likely to weed out suspicious claims and more likely to push reluctant plaintiffs 
to settle by raising litigation costs and signaling judicial approval of the deal. 
Using a dataset of products-liability MDLs that settled over the course of 
fourteen years,18 I found that judges in sixteen of thirty-four proceedings issued 
Lone Pine orders, or 47%. Of those, fifteen (93.7%) issued them after the first 
settlement date. This suggests that, at least in these MDL proceedings, Lone Pine 
 
16. Some lawyers have attributed this phenomenon to the role of lead generators and Internet 
advertising. Paul D. Rheingold, Multidistrict Litigation Mass Terminations for Failure to Prove 
Causation, ABA, (Apr. 24, 2019), https://www.americanbar.org/groups/litigation/commit-
tees/mass-torts/articles/2019/summer2019-multidistrict-litigation-mass-terminations-for-
failure-to-prove-causation [https://perma.cc/2A5P-GZRP]. 
17. Settlements typically include “grids,” which group claimants by injury category and payouts. 
18. My dataset includes all products-liability proceedings pending on the MDL docket as of May 
2013 that concluded in a private, aggregate settlement before May 2018 (thirty-four of the 
seventy-three proceedings, except the asbestos litigation, for which early electronic records 
were unavailable). See Figure 2 for those outcomes. I have recently made all of the data and 
documents publicly available and searchable at MDL Docs, U. GA. SCH. L., https://mdl 
.law.uga.edu [https://perma.cc/W4Y2-CJWL]. Focusing on aggregate settlements filtered 
out class actions and homed in on personal-injury proceedings, which are more likely to re-
quire innovative case-management techniques such as Lone Pine orders and plaintiff fact 
sheets. Those thirty-four proceedings settled over the course of fourteen years and collectively 
resolved 190,875 actions.  
This dataset is the subject of MASS TORT DEALS: BACKROOM BARGAINING IN MULTIDIS-
TRICT LITIGATION 223-26 (2019), except that I further updated and refined my research in this 
Essay to include recently-issued Lone Pine orders and to exclude most “show cause” orders, 
which the book included. I looked on the MDL dockets for orders that judges either labeled 
as “Lone Pine orders” (or referred to as such in subsequent transcripts) or that required plain-
tiffs to provide prima facie evidence of causation (typically with an expert report). I did in-
clude the first of several show cause orders from Zimmer Durom Hip Cup. The judge in that 
proceeding specified that she issued the order “[f]or the reasons set forth on the record,” but 
that transcript is currently unavailable. Order Granting Zimmer, Inc. and Zimmer Holdings, 
Inc.’s Motion for Order to Show Cause, In re Zimmer Durom Hip Cup Prods. Liab. Litig., 
No. 2:09-cv-04414-SDW-MCA (D.N.J. Mar. 8, 2019). Subsequent information may suggest 
excluding it. For information on Engstrom’s dataset, see Engstrom & Espeland, supra note 11, 
at 9-10. 
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orders do not winnow meritless claims pre-settlement.19 It’s the settlement’s 
claims administrators who decide which claims warrant compensation, not 
judges. Of course, not all noncompensable claims are “meritless”; some may 
simply fall outside the strict parameters that settling parties negotiate. In the 
massive Vioxx settlement, for example, the claims administrator asked for addi-
tional information on 256 potentially fraudulent claims, and did not get a re-
sponse on 194.20 Of the sixty-two who responded, thirty-nine overcame the ini-
tial suspicion (46%), and Judge Fallon later reported that only two out of 50,000 
claims were fraudulent.21 
Looking at the bigger picture, the first settlements in those thirty-four pro-
ceedings occurred, on average, 1,234 days (or three years and 4.5 months) after 
the Panel centralized them. And the judges who issued Lone Pine orders within 
those proceedings did so on average 1,411 days (or three years and 10.3 months) 
after centralization.22 Although not all of the proceedings have closed and the 
difference is not statistically significant in this sample, closed proceedings with 
Lone Pine orders ended no sooner than those without them. More specifically, 
the ten closed proceedings that issued Lone Pine orders concluded an average of 
3,304 days (or a little over nine years) after centralization, whereas the eight pro-
ceedings that did not issue them closed an average of 2,904 days (or less than 
eight years) after centralization—over a year sooner.23 
 
19. Only Fosamax issued a pre-settlement Lone Pine order, though it issued a second one after a 
global settlement as well. Pre-settlement Lone Pine Order, In re Fosamax Prods. Liab. Litig., 
No. 06-MD-1789 (S.D.N.Y. Nov. 20, 2012); Lone Pine Order, In re Fosamax, No. 06-MD-1789 
(S.D.N.Y. July 30, 2014). This finding is consistent with Engstrom’s. See Engstrom & Es-
peland, supra note 11, at 14 (“Generally, these twilight orders were issued in the MDL context, 
after the lead plaintiffs’ attorneys had hammered out a tentative settlement agreement and 
were, often in concert with the defendant, trying to corral the remaining plaintiffs to opt in.”). 
20. Report by the Claims Administrator on Potentially Fraudulent Claims Filed in the Nation-
wide Vioxx Consumer Settlement Program, In re Vioxx Prods. Liab. Litig., No. 05-md-01657 
(E.D. La. Feb. 25, 2015). Proceedings, like those over pelvic mesh, that settle on an “inventory,” 
or firm-by-firm basis, may be different. But thus far in those proceedings, Judge Joseph Good-
win has not used Lone Pine orders. 
21. Status Conference at 59, In re Vioxx, No. 05-md-1657 (E.D. La. July 27, 2010). 
22. See infra Appendix Table A1 for detailed information. 
23. Closed proceedings using Lone Pine orders included an average of 3,304 actions, versus 2,904 
average actions for closed proceedings that did not use them. This suggests that judges may 
be more inclined to issue Lone Pine orders in larger proceedings. 
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Figure 1. 
timeline of mdl events within the dataset24 
 
As Figure 1 illustrates, 97.3% of these Lone Pine orders applied post-settlement 
only to non-settling plaintiffs. If Lone Pine orders do not screen cases pre-settle-
ment, then judges must issue them for a different reason entirely. As twilight 
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orders that follow on the heels of a private deal, Engstrom aptly observes that 
these Lone Pine orders can have a “dark side”—“to strongarm claimants to accede 
to a settlement agreement that they would rather refuse.”25 Thus, any study of 
Lone Pine orders in mass-tort MDLs must begin with an understanding of how 
those private settlements work, a task to which we now turn. 
A. Settlement Dynamics in MDLs 
Settlement designers in both mass-tort deals and class-action settlements 
want to include as many people as possible to give defendants all-inclusive relief. 
Class-action settlements can work like sticky flypaper: dealmakers aim to keep 
class members from opting out through most-favored nation provisions, walka-
way clauses, and even liens on the defendant’s assets in favor of settling class 
members.26 Inertia helps. Class members are bound by the deal unless they opt 
out, so the default position promotes closure for defendants. Yet, Rule 23 in-
cludes some safeguards for absent class members—notice, opt-out rights, objec-
tions, judicial settlement approval, and adequate representation.27 
But imagine a scenario without those class-action protections, where a client 
becomes a number, not a name, and is represented by the same attorney who 
represents hundreds of others. Imagine further that only one common factual 
question is needed to centralize those cases before the same judge and that the 
judge does not appoint lead plaintiffs’ lawyers to ensure that they adequately 
represent the spectrum of competing interests. Instead, judges appoint leaders 
based on attorneys’ expertise, tendency to cooperate with others, and ability to 
fund the suits.28 That’s what happens before mass torts conclude in private, ag-
gregate settlements, as 47.9% of all products-liability proceedings in the dataset 
ultimately did. Unlike class settlements, where everyone is automatically “in,” 
plaintiffs’ attorneys must convince their clients to settle—to affirmatively act—
 
24. Products-liability proceedings see some major events that can affect their duration. Looking 
over a proceeding’s lifecycle shows when these events occur and how quickly they facilitate 
closure. My deepest thanks to Margaret S. Williams for creating this visual.  
25. Engstrom, supra note 1, at 36. 
26. See e.g., Richard A. Nagareda, The Preexistence Principle and the Structure of the Class Action, 103 
COLUM. L. REV. 149, 204-19 (2003). For more detail on the effects of walkaway clauses in 
MDLs, see Elizabeth Chamblee Burch, Monopolies in Multidistrict Litigation, 70 VAND. L. REV. 
67, 92-94 (2017). 
27. FED. R. CIV. P. 23. Not that class actions are perfect—far from it. See, e.g., Reynolds v. Beneficial 
Nat’l Bank, 288 F.3d 277 (7th Cir. 2002) (scrutinizing the role of the plaintiffs’ attorneys and 
ultimately rejecting a collusive class-action settlement). 
28. BURCH, supra note 7, at 90-96; Burch & Williams, supra note 12, at 1460-63. 
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to satisfy defendants’ closure goals. That is where the ethical conundrums and 
the “dark side” that Engstrom alludes to begin. 
Figure 2.  
how do product-liability mdls end?29 
 
Understanding how these deals work requires a bit of terminology and ex-
planation. In this context, the word “settlement” is a misnomer—the private 
agreements do not actually settle anything. They are deals between the lead 
plaintiffs’ lawyers and the defendant that set up settlement programs. This is key, 
because the terms require plaintiffs’ lawyers to do a little arm-twisting before an 
actual settlement occurs.30 
For example, every publicly available private deal in the dataset included a 
“walkaway” clause, meaning that the defendant could abandon the settlement 
 
29. See infra Appendix Table A2 for detailed information.  
30. BURCH, supra note 7, at 40-54. 
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offer if too few plaintiffs signed up.31 To measure compliance and identify the 
denominator for the walkaway percentage, some leaders request a “census” or-
der, as Figure 1 showed. Although lead lawyers could count federal cases on their 
own, they want a full roll call that identifies state-court plaintiffs and unfiled 
claims. So they enlist the court’s help: judges in 35% of the thirty-four proceed-
ings required attorneys to register all of their clients, regardless of where (or 
whether) they filed those claims.32 
Meeting walkaway percentages, which require between 85% and 100% of 
plaintiffs to enter the program, means plaintiffs’ lawyers must corral as many 
clients as possible or risk blowing up the offer and not getting paid.33 Entering 
the program, however, requires plaintiffs to dismiss their lawsuit with preju-
dice.34 Yet, in 60% of the private settlements, plaintiffs had little idea how 
much—if anything—they would actually receive.35 Informed consent is therefore 
a stretch.36 
That takes out carrots and leaves us with the real stick: ethically dubious 
clauses that require plaintiffs’ attorneys to recommend that all of their clients 
settle and to withdraw from representing clients who refuse.37 Non-settling cli-
ents find themselves between a rock and a hard place.38 In corresponding with 
pelvic-mesh plaintiffs as part of an ongoing study,39 for example, one plaintiff 
told me “I let [my law firm] know that I do NOT want them to dismiss my case 
 
31. Ten of the thirty-four proceedings ending in private, aggregate settlements made those set-
tlements publicly available. Three of the ten had two settlements each, for a total of thirteen. 
32. BURCH, supra note 7, at 118. 
33. Id. at 44-45. 
34. It thus becomes extremely difficult, if not impossible depending on the proceeding, to tell 
whether a dismissal on the docket results from entering into a settlement program or failing 
to comply with a court order. 
35. BURCH, supra note 7, at 140; Paul D. Rheingold, In Mass Torts, Who Speaks for the Individual 
Plaintiffs?, LEGAL CURRENT (Feb. 23, 2017), http://www.legalcurrent.com/in-mass-torts 
-who-speaks-for-the-individual-plaintiffs [https://perma.cc/ZC59-JGAR] (“As I consider 
recent settlements, many were so complex and mechanistic that I could not predict what my 
clients would get by way of settlement—yet, they had to sign a release as a pre-condition for 
entering into the settlement plan.”). 
36. BURCH, supra note 7, at 137-44; Howard M. Erichson & Benjamin C. Zipursky, Consent Versus 
Closure, 96 CORNELL L. REV. 265, 281-92 (2011); Nancy J. Moore, Ethical Issues in Mass Tort 
Plaintiffs’ Representation: Beyond the Aggregate Settlement Rule, 81 FORDHAM L. REV. 3233, 3252-
57 (2013). 
37. Burch & Williams, supra note 12, at 1502-08. 
38. BURCH, supra note 7, at 43-54; Elizabeth Chamblee Burch, Monopolies in Multidistrict Litigation, 
70 VAND. L. REV. 67, 90-102 (2017). 
39. This project will be ongoing at least until the end of November 2019. Procedural Justice Study 
on Women’s Health Multidistrict Litigation, ELIZABETH CHAMBLEE BURCH, https:// 
www.elizabethchambleeburch.com/womens-mdls [https://perma.cc/NJ8D-ASGZ]. 
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[to enter a settlement program]. They have told me that means I will likely be 
dropped from them . . . . Right now they are trying to bully me, and that just 
isn’t working!”40 
To make matters worse, these mandatory recommendation and withdrawal 
provisions tend to appear alongside simultaneous agreements for attorneys not 
to solicit or accept new clients.41 So, if that plaintiff declined to settle and her 
attorney withdrew from representing her, she may have to proceed pro se—not 
a simple task for injured plaintiffs laden with medical bills, especially when Lone 
Pine orders demand expensive expert proof.42 
Withdrawing from representing a client midstream typically necessitates ju-
dicial approval.43 In 35% of the thirty-four proceedings, judges acquiesced. Oth-
ers were “systematic in not permitting withdrawal.”44 Adaptive lawyers, how-
ever, have engineered workarounds in their contingency-fee agreements. Some 
build escape hatches: one firm incorporated an exit clause that allowed it to get 
out of its client obligations at any time.45 Others include deterrents: one firm 
required a client to reimburse it for her litigation expenses if she went against 
counsel’s settlement advice and insisted on going to trial but ultimately lost.46 
As Judge Jack B. Weinstein recognized, “[t]heoretically, each client has the 
option of rejecting his share of a settlement . . . . In practice, the attorney almost 
always can make a global settlement and convince the clients to accept it.”47 But 
as the terms Lone Pine orders, census orders, and withdrawal orders suggest, 
 
40. Elizabeth Chamblee Burch, Updated: When Trial is Too “Expensive” for Law Firms, MASS TORT 
LITIG. BLOG (Apr. 25, 2019), https://lawprofessors.typepad.com/mass_tort_litigation
/2019/04/updated-when-trial-is-too-expensive-for-law-firms.html [https://perma.cc/EZB7
-6AGD]. 
41. BURCH, supra note 7, at 50-53. 
42. BURCH, supra note 7, at 46-52. 
43. Of the thirteen private settlements that were publicly available, 53% contained withdrawal 
provisions. BURCH, supra note 7, at 45 (including Propulsid I & II, Vioxx, Fosamax, and Ameri-
can Medical Systems, which require a certain percentage of plaintiffs to participate, and DePuy 
ASR I & II, which allows the defendant to expel noncompliant law firms). 
44. Transcript of Status Conference at 16, In re Fresenius GranuFlo/Naturalyte Dialysate Prods. 
Liab. Litig. (D. Mass. Dec. 14, 2016). 
45. See e.g., Complaint at 34, Contingency Fee Retainer Agreement, Plummer v. McSweeney, No. 
4:18-cv-00063 (E.D. Ark. Jan. 24, 2018) (“Counsel may withdraw from Client’s representa-
tion at any time, upon reasonable written notice to Client at Client’s last known address.”). 
46. Motley Rice LLC Contract of Representation at ¶ 7 (“Should Motley Rice and/or co-counsel 
recommend settling my claims(s) but I elect to proceed to trial, if no monetary damages are 
recovered at trial, my attorneys will have the right to collect from me reasonable expenses 
incurred in this litigation.”) (on file with author). 
47. Jack B. Weinstein, Ethical Dilemmas in Mass Tort Litigation, 88 NW. U. L. REV. 469, 521 n.212 
(1994). 
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attorneys are not alone in their settlement-inducing endeavor. Judges nudge too. 
In 64.7% of those thirty-four proceedings, judges formally appointed the private 
claims administrator or settlement master.48 And, to varying degrees, 52.9% “ap-
proved” the private settlements despite having no formal statutory authority to 
do so.49 
Approving settlements and appointing claims administrators imprints the 
deal with a judicial imprimatur. In the In re Fresenius GranuFlo litigation, Judge 
Douglas Woodlock observed, “it is nice to be asked to provide an imprimatur,” 
but “[it is] to some degree not my responsibility to provide imprimaturs to var-
ious kinds of things [like appointing a settlement master] . . . . I try not to exer-
cise my jurisdiction when . . . it is the judicial equivalent of a blurb on the back 
of a new best seller.”50 
But 52.9% of judges felt differently. Judicially endorsing a private deal legit-
imizes it. Yet none of those proceedings adversarially aired the deal’s pros and 
cons. Judges did not write an opinion reasoning through whether the settlement 
was fair, reasonable, or adequate, as they would in approving a class settlement. 
Nor did they decide whether lead lawyers adequately represented plaintiffs with 
conflicting interests.51 In some instances, judges blessed the deal before ever rul-
ing on the merits: judges in only 50% of those thirty-four proceedings had made 
at least three merits-related rulings (summary judgment, Daubert motions, class 
certification, or presiding over a bellwether trial) before the first settlement and 
any subsequent Lone Pine order occurred.52 In four proceedings, judges issued 
post-settlement Lone Pine orders without making a single merits-related ruling 
beforehand.53 
B. Lone Pine Orders in MDLs 
The Pradaxa suits aptly illustrate how Lone Pine orders enter into MDL case 
management and settlement dynamics. In Pradaxa, Judge David Herndon never 
held a bellwether trial nor ruled on summary judgment, Daubert, or class 
 
48. BURCH, supra note 7, at 116-17. 
49. Id. at 104-119, 130-33 (discussing judges’ lack of authority to endorse private settlements). 
50. Transcript of Status Conference at 6-7, In re Fresenius GranuFlo/Naturalyte Dialysate Prods. 
Liab. Litig. (D. Mass. Apr. 29, 2016). 
51. BURCH, supra note 7, at 90-96. 
52. Id. at 110. 
53. Those proceedings included In re Avandia Mktg. Sales Practices & Prods. Liab. Litig., No. 07-
MD-1871 (E.D. Pa.); In re Gadolinium-Based Contrast Agents Prods. Liab. Litig., Nos. 1:08 
GD 50000 (N.D. Ohio); In re Ortho Evra Prods. Liab. Litig., No. 1:06-cv-40000 (N.D. 
Ohio); In re Pradaxa (Dabigatran Etexilate) Prods. Liab. Litig., No. 3:12-md-2385-DRH-
SCW (S.D. Ill.); see also BURCH, supra note 7, at 246-65. 
the yale law journal forum November 4, 2019 
76 
certification.54 He urged the parties to settle and, once they did, issued a flurry 
of orders. He stayed the proceeding, which meant nonsettling plaintiffs could 
not continue discovery or have their cases remanded.55 He issued a census so that 
all attorneys with a case before him had to include eleven categories of infor-
mation for all of their clients—regardless of where (or even whether) they had 
filed suit, and regardless of whether the client wanted to settle.56 
Judge Herndon then appointed the private claims administrator and im-
posed additional discovery burdens on non-settling plaintiffs via a Lone Pine or-
der.57 Under the order, non-settling plaintiffs had approximately fifteen days af-
ter the settlement’s opt-in deadline to produce fact sheets, affidavits, and 
pharmacy and medical records dating back to five years before their alleged in-
jury occurred. In total, plaintiffs had a little over two months to comply with the 
Lone Pine order by producing an expert report on both general and specific cau-
sation. If they failed, they had just twenty days to fix the deficiency—a deadline 
that could not be extended.58 
That is the Lone Pine order’s power. Perhaps now we can see those twilight 
orders for what they are in MDLs: a cleanup device, not a screening tool. Color-
fully described by plaintiffs’ leadership as “a post-settlement mop-up proce-
dure,” and by defendants as a “put up or shut up” device, settlement designers 
use Lone Pine orders to signal that plaintiffs should either settle or prepare to 
prove their claims immediately without the procedural protections of summary 
judgment.59 
With Lone Pine orders positioned as MDL settlements’ billy club, I would go 
further than Engstrom and suggest that they should fail her test per se in the 
MDL context. She suggests that judges must use Lone Pine orders only as a last 
resort when no other tools suffice, or when credible evidence casts doubt on 
 
54. BURCH, supra note 7, at 110-13. 
55. Minute Order, In re Pradaxa, No. 3:12-MD-02385-DRH-SCW (S.D. Ill. May 28, 2014). 
56. Case Management Order No. 77, In re Pradaxa, No. 3:12-MD-02385-DRH-SCW (S.D. Ill. 
May 29, 2014). 
57. Case Management Order No. 78, In re Pradaxa, No. 3:12-MD-02385-DRH-SCW (S.D. Ill. 
May 29, 2014); BURCH, supra note 7, at 110-13. 
58. Case Management Order No. 78, supra note 57. Appendix Table A1 includes the timeframe 
that other courts have used for issuing similar orders. 
59. Order, In re Fosamax Prods. Liab. Litig., No. 1:06-md-01789-JFK-JCF (S.D.N.Y. July 30, 
2014) (quoting Plaintiffs Steering Committee’s Memorandum of Points and Authorities in 
Opposition to Defendant Merck’s Motion for Entry of Lone Pine Order at 7, In re Fosamax, 
No. 1:06-md-01789-JFK-JCF (S.D.N.Y. Oct. 29, 2012)); Transcript of Proceedings at 59, In 
re Biomet M2A Mangum Hip Implant Prods. Liab. Litig., No. 3:12-md-02391–RLM-CAN 
(N.D. Ind. May 18, 2015) (quoting defense attorney John Winter). 
nudges and norms in multidistrict litigation 
77 
some or all of plaintiffs’ claims (or dilatory plaintiffs persist).60 But ready-made 
rules and statutory remands exist for all non-settling MDL plaintiffs. So, there 
is no need for Lone Pine orders to function as a gap filler.61 And, as Engstrom 
readily notes, “a plaintiff’s refusal to acquiesce to a global settlement should 
inform neither prong of the analysis.”62 
Claims that remain post-settlement tend to stem from one of two kinds of 
plaintiffs: nonresponsive plaintiffs63 or plaintiffs who want a trial. Lone Pine 
orders do not distinguish between the two. They hit both with a heavy 
procedural burden that mimics summary judgment but lacks its safeguards. 
Separating these categories shows that existing procedures aptly address both 
situations, meaning that Lone Pine orders would not survive Engstrom’s first 
hurdle. 
First, when nonresponsive plaintiffs refuse to settle, their cases should still 
be in discovery.64 If plaintiffs refuse to respond to discovery queries, Rule 37 
supplies a series of steps and sanctions: attempts to confer in good faith, an order 
compelling disclosure or a response, then an array of possible sanctions that 
range from deeming disputed facts established to dismissing the action. 
Second, when non-settling plaintiffs want to try their cases, they will 
respond to discovery requests and should be able to return to their original 
district once pretrial matters conclude. After all, multidistrict litigation is 
supposed to be for pretrial purposes only.65 In practice, however, only around 
3% of all actions transferred have ever been remanded.66 
As Judge Eduardo Robreno, who handled and remanded many of the 
asbestos cases, explained, “As a matter of judicial culture, remanding cases is 
viewed as an acknowledgement that the MDL judge has failed to resolve the 
case . . . .”67 That stigma should change. But vanity is no excuse for a Lone Pine 
order, especially when remanding cases can perform the same function. Once 
 
60. Engstrom, supra note 1, at 54-55. 
61. Id. at 55. 
62. Id. at 56 n.231. 
63. Plaintiffs’ nonresponsiveness may result from counsel’s poor job of keeping up with her 
clients. 
64. In practice, nonsettling plaintiffs face a discovery stay—another tool that pushes settlement. 
BURCH, supra note 7, at 119, 258-65. 
65. See 28 U.S.C. § 1407(a) (2018). 
66. See Table S-20: Cumulative Summary of Multidistrict Litigation During the 12-Month Periods End-
ing September 30, 2016 Through 2018, U.S. COURTS (2018), https://www.uscourts.gov 
/sites/default/files/data_tables/jb_s20_0930.2018.pdf [https://perma.cc/7ATN-2YV3]. 
67. Eduardo C. Robreno, The Federal Asbestos Product Liability Multidistrict Litigation (MDL-875): 
Black Hole or New Paradigm?, 23 WIDENER L.J. 97, 144 (2013). 
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remanded, a defendant can move for summary judgment on specific causation 
and, if the plaintiff prevails, she can insist on her day in court.68 
i i .  a critical look at plaintiff fact sheets 
Siphoning claims pre-settlement falls to another judicially concocted order: 
plaintiff fact sheets. Unlike party-driven discovery devices in routine cases, this 
judge-issued order requires plaintiffs to provide defendants with specific 
information about their individual claims, circumstances, and injuries. As Figure 
1 illustrates, all but one of the thirty-four proceedings (97%) used a plaintiff fact 
sheet. Engstrom suggests that streamlined fact sheets “have effectively culled 
meritless claims” with less expense and fewer disadvantages than Lone Pine 
orders.69 
As I explain in this Part, however, I have reservations: like Lone Pine orders, 
fact sheets short circuit tried-and-true discovery rules as well as their built-in 
protections and limits. As they have evolved over time, some have become 
increasingly burdensome. Once again, that burden tends to fall 
disproportionately on plaintiffs. 
Like Engstrom, I see some upside to narrowly tailored fact sheets: they give 
both sides data on the proceeding’s scope in terms of claims, damages, and 
numbers. When centralized into a repository that the judge can access, they can 
help select representative bellwether cases. And, once a plaintiffs’ steering 
committee decides which claims to develop and pursue, they can identify cases 
falling outside those parameters that should be remanded without having to wait 
for the MDL to run its course.70 Perhaps they winnow cases, too. But apart from 
a preliminary report by the Federal Judicial Center, there has been no systematic 
study documenting fact sheets’ use or effect.71 
Overall, I have two concerns. First, I worry about the cumulative impact ad 
hoc procedures have on plaintiffs. And second, I worry about Engstrom’s 
 
68. BURCH, supra note 7, at 207-15 (promoting the use of episodic remands). 
69. Engstrom, supra note 1, at 58. 
70. BURCH, supra note 7, at 207-15 (promoting the use of episodic remands for plaintiffs who fall 
outside the scope of the claims the steering committee decides to develop). 
71. The Federal Judicial Center prepared a study for the Judicial Conference Advisory Committee 
on Civil Rules, which showed docket evidence of dismissals in 55% of the proceedings in 
which judges ordered fact sheets. Margaret S. Williams et al., Plaintiff Fact Sheets in Multidis-
trict Litigation: Products Liability Proceedings 2008-2018, FED. JUD. CTR. 4 (Mar. 2019), 
https://www.fjc.gov/sites/default/files/materials/49/PFS%20in%20MDL.pdf [https:// 
perma.cc/JZ3V-EADN]. An in-depth study of fact sheets is coming soon. Margaret S. Wil-
liams & Jason A. Cantone, Fact Sheets in Mass Tort Multidistrict Litigation Proceedings, 2008-
2018 (forthcoming) (on file with author). 
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recommendation that courts strengthen the consequences for plaintiffs who do 
not comply with fact sheet orders. As I explore in this Part, plaintiffs’ attorneys 
may not communicate with their clients as much as we would hope and even 
diligent plaintiffs may face barriers to obtaining their medical records. So, 
raising the stakes for noncompliance by subjecting plaintiffs to a Lone Pine order 
and then dismissing their claims with prejudice may be unjust.72 
Like other ad hoc inventions, fact sheets lack standardization and are only 
loosely tethered to the discovery rules. They thus suffer from two of the 
pathologies that Engstrom identified with Lone Pine orders—they are 
inconsistent and unpredictable, and may be out of step with the formal 
procedural scheme.73 
First, plaintiff fact sheets fluctuate in timing, name, compliance, content, and 
consequences. As plaintiffs face ever-changing burdens and deadlines, concerns 
arise about treating like plaintiffs alike. Although nearly all judges in my dataset 
ordered fact sheets, they did so at different times, ranging from forty-five to 
1,084 days after the Panel centralized the proceeding. On average, judges 
required plaintiff fact sheets 248.8 days post-centralization,74 but called them 
different things. Some referred to fact sheets as plaintiff profile forms,75 which 
generally required less information (and were sometimes a precursor to a fact 
sheet), while others termed follow-on fact sheets a “supplemental discovery 
obligation,” which required an expert report (like a Lone Pine order).76 
Plaintiff fact sheets likewise varied substantially on compliance deadlines, 
which spanned from thirty to 120 days.77 Although rolling deadlines make sense 
given that cases enter a multidistrict proceeding at different times, deadlines 
depended on everything from the first letter of the plaintiff’s last name,78 what 
 
72. See Engstrom, supra note 1, at 60. Engstrom notes that plaintiffs should have reasonable time 
to cure deficiencies first. 
73. See id. at 37-46. Fact sheets have, however, been upheld on appellate review. See, e.g., In re 
Phenylpropanolamine (PPA) Prods. Liab. Litig., 460 F.3d 1217, 1237 (9th Cir. 2006); In re 
Guidant Corp. Implantable Defibrillators Prods. Liab. Litig., 496 F.3d 863 (8th Cir. 2007). 
74. This is around eight months, which is consistent with the Federal Judicial Center’s study 
finding that the average time was 8.2 months. See Williams et al., supra note 71, at 3. 
75. See, e.g., Pretrial Order No. 9 Plaintiff Profile Form/Execution of Authorizations, In re Pro-
pulsid Prods. Liab. Litig., No. 00-md-01355 (E.D. La. Jan. 31, 2001). 
76. See Pretrial Order No. 102, In re Baycol Prods. Litig., No. 01-md-01431 (D. Minn. Jan. 16, 
2004). 
77. BURCH, supra note 7, at 258-65. 
78. E.g., Pretrial Order No. 18A, In re Vioxx Prods. Liab. Litig., No. 2:05-md-01657 (E.D. La. Aug. 
17, 2005). 
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“wave” or “phase” the plaintiff’s case fell into,79 and when the plaintiff filed her 
complaint,80 to the transfer date81 and whether the plaintiff entered a tolling 
agreement.82 
As one would expect, fact sheets sought different information. In general, 
however, they requested (1) medical and pharmacy records, (2) personal 
background information, and (3) a plaintiff’s litigation history—from previous 
tort claims to employment lawsuits to bankruptcy.83 The first two categories 
appear tied to a hodgepodge of discovery rules, but the third makes little sense. 
Prior lawsuits unrelated to the current claim are not “relevant to any party’s claim 
or defense” under Rule 26, nor do they have a tendency to prove or disprove a 
fact that matters under substantive tort law, likely rendering them irrelevant 
under evidentiary rules.84 The only plausible inference a jury could draw from 
that information would be a forbidden and often unsupportable one: that this is 
an overly litigious person who probably has a frivolous claim.85 
These idiosyncrasies raise the second concern: plaintiff fact sheets, like Lone 
Pine orders, can be out of step with the formal procedural scheme. Their 
requested content reads like a pancaked version of initial disclosures, 
interrogatories, requests to produce documents, and deposition queries, but 
without each rule’s prepackaged protections and limits. For instance, some 
judges deem fact sheets “interrogatories” under Rule 33, which imposes a 
twenty-five-question limit, including subparts. But fact sheets often exceed 100 
questions and seek information that one would ordinarily expect to convey when 
deposed or to send as part of Rule 26’s initial disclosures.86 
In a run-of-the-mill case, parties must send initial disclosures at least 
fourteen days after the Rule 26(f) conference, which occurs “as soon as 
 
79. See, e.g., Pretrial Order No. 2, In re Mirapex Prods. Liab. Litig., No. 07-md-01836 (D. Minn. 
Sept. 5, 2007); Pretrial Order No. 4, In re Levaquin Prods. Liab. Litig., No. 08-md-01943 (D. 
Minn. Feb. 20, 2009). 
80. See, e.g., Pretrial Order No. 7, In re Avandia Mktg., Sales Practices & Prods. Liab. Litig., No. 
07-md-01871 (E.D. Pa. June 9, 2008). 
81. E.g., Case Management Order No. 2, In re Zimmer Nexgen Knee Implant Prods. Liab. Litig., 
No. 1:11-cv-05468 (N.D. Ill. Dec. 23, 2011). 
82. See e.g., Pretrial Order No. 7, supra note 75. 
83. Williams et al., supra note 71, at 2. 
84. FED. R. CIV. P. 26(b)(1); FED. R. EVID. 401. Questions about prior litigation history are likely 
a relic from fact sheets’ origins in the Silica litigation. See Order No. 6 at ex. A, In re Silica 
Prods. Liab. Litig., No. 03-md-01553 (S.D. Tex. Feb. 5, 2004). 
85. This inference would likely be excluded under Federal Rule of Evidence 403’s balancing test 
because it has little-to-no relevance to substantive law and any probative value would be sub-
stantially outweighed by the danger of unfair prejudice. 
86. See e.g., Pretrial Order No. 40, In re Ethicon, Inc., Pelvic Repair Sys. Prods. Liab. Litig., No. 
2:12-md-02327 (S.D.W.V. Mar. 6, 2013). 
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practicable.”87 And then, once served with interrogatories and requests to 
produce documents, parties have thirty days to respond, unless the court orders 
otherwise.88 In the usual sequencing, then, most plaintiffs will know several 
months in advance what lies ahead and what documents they will likely need to 
gather. But in an MDL, their case might be transferred as a “tag-along” action 
such that an order for fact sheets greets them upon arrival. Most judges take care 
to give these new arrivals longer deadlines, and rightfully so, but there are no 
guarantees. 
Timing can matter, especially when it comes to medical records and device 
injuries, which can entail multiple explant surgeries, specialists, and years of 
follow-up care. One pelvic-mesh plaintiff explained that she had seen over 
seventy-five different doctors in thirteen years and had eight mesh-related 
surgeries.89 And a 2018 study on U.S. News & World Report’s top-ranked 
hospitals found that even patients with less-extensive medical histories can face 
“long waiting periods and unclear request processes” for their records.90 While 
some hospitals made electronic and paper records available almost immediately, 
others took four to eight weeks and charged over $280 for a 200-page record.91 
Even among these top hospitals, the report found “a lack of transparency” in the 
request process, noncompliance with HIPAA’s recommended fees, and 
“processing times longer than the state-required time.”92 
When ongoing treatment and records requests pose obstacles to gathering 
the information that fact sheets seek, lenience—not stricter penalties for 
noncompliance—should be the norm. Yet the consequences for noncompliance 
fluctuated substantially.93 Most judges gave plaintiffs a chance to “cure” any 
 
87. FED. R. CIV. P. 26(f). 
88. FED. R. CIV. P. 33(b)(2), 34(b)(2)(A). 
89. “I have seen 8 GI doctors, 1 oncologist, 9 [OBGYNs], 2 infectious disease doctors, 1 proctol-
ogist, 3 pelvic reconstructions specialists, 2 plastic surgeons, 9 urologists, 4 dermatologists, 4 
allergists, 5 physical therapists, 11 primary care providers, 1 foot doctor, 2 endocrinologists, 1 
ophthalmologist, 3 rheumatologists. Then because of not being treated and gaslighted and 
emotionally abused by doctors, 3 psychiatrists, 3 psychologists, 3 counselors,” she wrote. Her 
identity is confidential. She is one of the many amazing women with whom I have interacted 
as part of an ongoing procedural justice study on women’s health multidistrict proceedings. 
See Procedural Justice Study on Women’s Health Multidistrict Litigation, ELIZABETH CHAMBLEE 
BURCH, https://www.elizabethchambleeburch.com/womens-mdls [https://perma.cc/5X2E 
-FGBE]. 
90. Carolyn T. Lye et al., Assessment of US Hospital Compliance with Regulations for Patients’ Requests 
for Medical Records, JAMA NETWORK OPEN 4-6 (Oct. 5, 2018). 
91. Id. at 4-6. 
92. Id. at 9. 
93. Compare Pretrial Order No. 28, In re Vioxx Prods. Liab. Litig., No. 05-md-1657 (E.D. La. Nov. 
9 2007) (giving plaintiffs twenty days to cure but refusing to grant any further extensions); 
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errors or omissions; but others were more draconian, allowing defendants to 
move to dismiss plaintiffs’ claims (without prejudice) thirty days after notifying 
them.94 
As a discovery tool, fact sheets should be governed by Rule 37, which sets up 
a predictable—yet flexible—sequence: defense counsel would move to compel 
only after certifying that she first conferred with opposing counsel in good faith. 
This, one hopes, eliminates motions to compel in cases where plaintiffs 
encounter roadblocks beyond their control. If defendants do move to compel, 
noncompliant plaintiffs’ counsel would have an opportunity to respond and be 
heard. Afterward, if a plaintiff still does not comply, the court may choose from 
a menu of options ranging from striking pleadings to dismissing the action in 
whole or in part.95 
As fact sheets evolve through norms that operate in the shadows of formal 
discovery rules, it is not just their variety and unpredictability that is 
worrisome.96 Over time, as lawyers simply add to what is already there, the 
questionnaires can look more like a museum storeroom and less like a 
streamlined discovery tool. An early fact sheet in the Silica litigation sought just 
a few pages of basic questions,97 but some recent examples span forty-eight 
pages (with forms and all), exceed 100 questions, and seek fifteen years of 
medical history, ten years of employment history, and information on everything 
from divorces to children’s names, addresses, and birthdays.98 
With increased length, fact sheets’ aim may shift from discovery to 
harassment—something that Engstrom cautions against and that the federal 
rules committee explicitly considered when limiting parties to twenty-five 
interrogatories.99 Plaintiffs’ education levels vary and not all receive attorney 
 
with In re Composix Kugel Hernia Repair Patch Litig., No. 04-md-1842 (D.R.I. Dec. 6, 2007). 
In Kugel Mesh, the court subjected noncompliant plaintiffs to dismissal if “good cause for such 
dismissal is shown,” meaning that the plaintiff failed to submit a fact sheet, failed to complete 
a fact sheet, or failed to fill in material aspects of the fact sheet. The defendant had to send 
plaintiff’s counsel a letter of noncompliance, which triggered an additional forty-five days to 
comply. 
94. Order Regarding Completion of IH/PTC Plaintiff Fact Sheets, In re Mirena IUS Levonorg-
estrel-Related Prods. Liab. Litig. (No. II), No. 17-md-02767 (S.D.N.Y. Aug. 30, 2017). 
95. FED. R. CIV. P. 37. 
96. See Burch & Williams, supra note 12, at 1456-59 (observing the growth of ad hoc practices). 
97. Order No. 6, supra note 84, at ex. A. 
98. See, e.g, Pretrial Order No. 40, supra note 86; Pretrial Order No. 2, supra note 79; In re Zimmer 
Durom Hip Cup Prods. Liab. Litig., No. 09-cv-04414 (D.N.J. Jan. 31, 2013). 
99. FED. R. CIV. P. 33, 1993 advisory comm. note (“Experience in over half of the district courts 
has confirmed that limitations on the number of interrogatories are useful and manageable. 
Moreover, because the device can be costly and may be used as a means of harassment, it is 
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assistance. As representing mass-tort clients has turned into a wholesale business 
for many lawyers, some plaintiffs have never even spoken with their attorney. 
Third-party vendors (often owned by plaintiffs’ lawyers) have popped up to fill 
the gap, promising that “our Physicians in India prepare Plaintiff Fact Sheets for 
$35 an hour as a billable expense.”100 So, by using a third-party service, the 
money eventually comes out of plaintiffs’ pockets as a cost rather than attorneys’ 
contingency fees, thereby impacting plaintiffs’ bottom line. In short, while 
plaintiffs’ fact sheets aim to streamline discovery, in practice, they can bypass 
built-in discovery protections and impact parties disproportionately. 
conclusion 
It is true that multidistrict litigation should not abrogate defendants’ ability 
to discover plaintiff-specific information or the basic tenet that plaintiffs must 
prove their claims. But, as Engstrom acknowledges, judges should be mindful 
about overtaxing plaintiffs too—whether through Lone Pine orders or plaintiff 
fact sheets.101 Procedural justice dictates that procedural burdens should not fall 
disproportionally on one party. Rather, rules should distribute the risks of error 
and the costs of access as evenly as possible.102 Rule 26 strives to accomplish this 
by requiring that discovery remain proportional to a case’s needs. But as hand-
me-down procedures like plaintiff fact sheets and Lone Pine orders spread 
through common-law norms and escape formal rules’ rigorous vetting process, 
parity may dissolve.103 
Where does all of this leave us? On the one hand, transferee judges are right: 
every mass-tort proceeding differs in some respect, which suggests the need for 
flexibility over rigidity. On the other hand, when judges and parties invent 
procedures for a particular proceeding, they risk focusing on the pragmatics of 
that case, overlooking normative issues, and importing the baggage of their 
biases and thoughts about the proceeding. Achieving neutrality, where discovery 
 
desirable to subject its use to the control of the court consistent with the principles stated in 
Rule 26(b)(2), particularly in multi-party cases . . . .”); Engstrom, supra note 1, at 60 n.247. 
100. Plaintiff Fact Sheets, REC. REFORM, https://www.medquestltd.com/mass-torts/plaintiff-fact 
-sheets [https://perma.cc/WRW5-AKMK]. 
101. Engstrom, supra note 1, at 60 n.247. 
102. Lawrence B. Solum, Procedural Justice, 78 S. CAL. L. REV. 181, 257-58 (2004); Robert G. Bone, 
Agreeing to Fair Process: The Problem with Contractarian Theories of Procedural Fairness, 83 B.U. 
L. REV. 485, 514 (2003). 
103. In the Federal Judicial Center’s study, 42% of courts required defendant fact sheets, whereas 
57% required plaintiff fact sheets (87% of proceedings with 1,000 or more actions required 
plaintiff fact sheets). Williams et al., supra note 71. Still, searching company databases is un-
likely to be as burdensome as requiring plaintiffs to provide fifteen years of pharmacy and 
medical records. 
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burdens and the risks of erroneous decisions fall equally on both parties, may be 
hard in the heat of battle. Although design choices should respond to what is 
happening on the ground, issuing a Lone Pine order or a plaintiff fact sheet does 
not occur in a vacuum; those decisions have ripple effects that can impact 
plaintiffs more harshly than defendants.104 If judges experiment with bespoke 
procedures, they should take care to ensure a fair fit for both parties that works 
with—not against—off-the-rack rules. 
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104. See, e.g., Elizabeth J. Cabraser & Katherine Lehe, Uncovering Discovery, 12 SEDONA CONF. J. 1, 
8 n.40 (2011) (“In some cases, however, it appears to plaintiffs that the ‘fact sheet’ process 
does not save them time or money, as defendants have seized and developed fact sheets as a 
weapon of attrition, using shotgun ‘deficiencies’ (including typographical errors, failure to 
provide information as to questions marked ‘N/A,’ missing middle initials, etc.) to prolong 
the process and, as in PPA, to set up motions for dismissal as the ultimate sanction.”). 
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appendix 
TABLE A1  
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4,823 
Baycol. 1431 76 1,290 
   
Prempro  1507 406 3,384 
  
4,307 
Vioxx  1657 181 996 996 996 4,964 
Ortho Evra  1742 117 957 1,105 
 
3,234 
Human Tissue  1763 117 1,319 
  
2,694 
Fosamax  1789 122 2,775 2,286 
 
4,305 
Mirapex  1836 75 587 
   
Kugel Mesh 
Hernia Patch  
1842 167 1,470 1,796 
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1909 110 413 1,828 1,429 2,619 
the yale law journal forum November 4, 2019 
86 
Litigation 
Name MDL No. D
ay
s 
fr
om
 C
en
tr
al
iz
at
io
n
 t
o 
P
F
S
 
D
ay
s 
fr
om
 C
en
tr
al
iz
at
io
n
 t
o 
F
ir
st
 
S
et
tl
em
en
t 
  D
ay
s 
fr
om
 C
en
tr
al
iz
at
io
n
 t
o 
L
P
O
 
  D
ay
s 
fr
om
 C
en
tr
al
iz
at
io
n
 t
o 
C
en
su
s 
  D
ay
s 
fr
om
 C
en
tr
al
iz
at
io
n
 t
o 
C
lo
su
re
 
  
Trasylol  1928 45 820 1,129 
 
2,681 
Levaquin  1943 252 1,600 1,946 
 
3,323 
Heparin  1953 137 1,273 
 
1,434 3,031 
NuvaRing  1964 77 1,995 1,995 1,873 
 
Mentor Corp. 
ObTape.  
2004 1,084 552 
  
3,506 
Chantix  2092 146 1,387 
  
1,831 
Yasmin and Yaz  2100 153 1,261 1,261 2,132 3,382 
Zimmer  
Durom Hip 
Cup  
2158 968 2,073 3,194 2,165 
 
C.R. Bard  2187 238 1,715 
 
1,176 
 
DePuy ASR  2197 297 1,082 
 
1,085 
 
Zimmer 
Nexgen Knee 
Implant  
2272 137 2,374 2,352 2,256 
 
Actos 
(Pioglitazone
)  
2299 193 1,217 
 
1,216 2,309 
American 
Medical 
Systems 
2325 387 448 
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Boston  
Scientific  
2326 240 1,399 
   
Ethicon 2327 393 1,450 
   
Wright Medical  2329 105 1,728 
   
Watson 
Fentanyl 
Patch  
2372 
 
301 
  
738 
Pradaxa  2385 82 658 659 659 1,958 
Coloplast Corp.  2387 137 777 
   
Biomet  2391 174 486 
   
Fresenius 
GranuFlo
/NaturaLyte  
2428 252 1,223 1,399 629 
 
Tylenol  2436 80 1,411 1,423 
  
Average  248.8 1,234.70 1,411 1,414.7 1,348 
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TABLE A2 
JUDICIAL ASSIGNMENTS AND RESOLUTIONS IN THE MDL PRODUCTS-LIABILITY DATASET 
 
Judge Litigation Name 
MDL 
Number Outcome 
Eduardo  
C. Robreno In re: Asbestos Prod. Liab. Litig. (No. VI) 875 
Aggregate 
Settlement 
John  
Grady 
In re: Factor VIII or IX Concentrate Blood 
Products Prod. Liab. Litig. 986 
Class-action 
Settlement 
Harvey  
Bartle, III 
In re: Diet Drugs (Phentermine/Fenfluramine/ 
Dexfenfluramine) Prod. Liab. Litig. 1203 
Class-action 
Settlement 
Eldon  
E. Fallon In re: Propulsid Prod. Liab. Litig. 1355 
Aggregate 
Settlement 
Michael  
James Davis In re: Baycol Prod. Liab. Litig. 1431 
Aggregate 
Settlement 
William  
R. Wilson In re: Prempro Prod. Liab. Litig. 1507 
Aggregate 
Settlement 
James  
Moody, Jr. 
In re: Accutane (Isotrentinoin) Prod. Liab. 
Litig. 1626 
Defense 
Win 
Patti  
B. Saris 
In re: Neurontin Marketing, Sales Practices 
and Prod. Liab. Litig. 1629 
Class-action 
Settlement 
Eldon E. Fallon In re: Vioxx Prod. Liab. Litig. 1657 
Aggregate 
Settlement 
Esther  
Salas 
In re: Ford Motor Co. E-350 Van Prod. Liab. 
Litig. (No. II) 1687 
Defense 
Win 
Bernard 
Friedman 
In re: Ford Motor Co. Speed Control 
Deactivation Switch Prod. Liab. Litig. 1718 
Defense 
Win 
Rodney  
W. Sippel In re: Celexa and Lexapro Prod. Liab. Litig. 1736 
Individual 
Settlements 
David  
A. Katz In re: OrthoEvra Prod. Liab. Litig. 1742 
Aggregate 
Settlement 
Todd  
J. Campbell In re: Aredia and Zometa Prod. Liab. Litig. 1760 
Defense 
Win 
William  
J. Martini In re: Human Tissue Prod. Liab. Litig. 1763 
Aggregate 
Settlement 
John F. Keenan In re: Fosamax Prod. Liab. Litig. (MDL 1789) 1789 
Aggregate 
Settlement 
Michael  
James Davis In re: Mirapex Prod. Liab. Litig. 1836 
Aggregate 
Settlement 
Mary  
M. Lisi 
In re: Kugel Mesh Hernia Patch Prod. Liab. 
Litig. 1842 
Aggregate 
Settlement 
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Judge Litigation Name 
MDL 
Number Outcome 
Thomas W. 
Thrash, Jr. In re: ConAgra Peanut Butter Prod. Liab. Litig. 1845 
Aggregate 
Settlement 
Cynthia  
M. Rufe 
In re: Avandia Marketing Sales Practices and 
Prod. Liab. Litig. 1871 
Aggregate 
Settlement 
Kurt  
D. Engelhardt 
In re: FEMA Trailer Formaldehyde Prod. Liab. 
Litig. 1873 
Class-action 
Settlement 
Dan  
A. Polster 
In re: Gadolinium Contrast Dyes Prod. Liab. 
Litig. 1909 
Aggregate 
Settlement 
Donald M. 
Middlebrooks In re: Trasylol Prod. Liab. Litig. 1928 
Aggregate 
Settlement 
John  
R. Turnheim In re: Levaquin Prod. Liab. Litig. 1943 
Aggregate 
Settlement 
James  
Carr In re: Heparin Prod. Liab. Litig. 1953 
Aggregate 
Settlement 
Ann D. 
Montgomery In re: Zurn Pex Plumbing Prod. Liab. Litig. 1958 
Class-action 
Settlement 
Rodney  
W. Sippel In re: NuvaRing Prod. Liab. Litig. 1964 
Aggregate 
Settlement 
Ortrie  
D. Smith 
In re: Bisphenol-A (BPA) Polycarbonate 
Plastics Prod. Liab. Litig. 1967 
Class-action 
Settlement 
Christopher  
A. Boyko 
In re: Whirlpool Corp. Front-Loading Washer 
Prod. Liab. Litig. 2001 
Class-action 
Settlement 
Clay  
D. Land 
In re: Mentor Corp. ObTape Transobuturator 
Sling Prod. Liab. Litig. 2004 
Aggregate 
Settlement 
Andrew  
J. Guilford 
In re: Land Rover LR3 Tire Wear Products 
Liability Litigation 2008 
Class-action 
Settlement 
Brian  
M. Cogan 
In re: Bayer Corp. Combination Asprin Prod. 
Marketing and Sales Practices Litig. 2023 
Class-action 
Settlement 
James  
Ware 
In re: Apple iPhone 3G Products Liability 
Litigation 2045 
Defense 
Win 
Eldon  
E. Fallon 
In re: Chinese-Manufactured Drywall Prod. 
Liab. Litig. 2047 
Class-action 
Settlement 
Cecilia  
M. Altonaga In re: Denture Cream Products Liab. Litig. 2051 
Defense 
Win 
Inge P. Johnson In re: Chantix Prod. Liab. Litig 2092 
Aggregate 
Settlement 
David  
R. Herndon 
In re: Yasmin and Yaz (Drospirenone) 
Marketing , Sales Practices Prod. Liab. Litig. 2100 
Aggregate 
Settlement 
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Judge Litigation Name 
MDL 
Number Outcome 
Michael  
P. McCuskey In re: IKO Roofing Shingle Prod. Liab. Litig. 2104 Ongoing 
James  
V. Selna 
In re: Toyota Motor Corp. Unintended 
Acceleration Marketing, Sales Practices, and 
Products Liab. Litig. 2151 
Class-action 
Settlement 
Susan  
D. Wigenton 
In re: Zimmer Durom Hip Cup Prod. Liab. 
Litig. 2158 
Aggregate 
Settlement 
Cormac  
J. Carney 
In re: Toyota Motor Corp. Hybrid Brake 
Marketing, Sales Practices, and Products Liab. 
Litig. 2172 
Defense 
Win 
Carl  
J. Barbier 
In re: Oil Spill by the Oil Rig "Deepwater 
Horizon" in the Gulf of Mexico, on April 20, 
2010 2179 
Class-action 
Settlement 
Joseph  
R. Goodwin 
In re: C.R. Bard, Inc., Pelvic Repair System 
Prod. Liab. Litig. 2187 
Aggregate 
Settlement 
Ronald  
Whyte 
In re: Apple Inc. iPhone 4 Marketing, Sales 
Practices & Prod. Liab. Lit. 2188 
Class-action 
Settlement 
David  
A. Katz 
In re: DePuy Orthopaedics Inc., ASR Hip 
Implant Prod. Liab. Litig. 2197 
Aggregate 
Settlement 
Matthew  
F. Kennelley 
In re: Navistar 6.0 Diesel Engine Prod. Liab. 
Litig. 2223 
Class-action 
Settlement 
Danny  
C. Reeves 
In re: Darvocet, Darvon and Propoxyphene 
Prod. Liab. Litig. 2226 
Defense 
Win 
Gregory  
L. Frost 
In re: Porsche Cars North America Inc. Plastic 
Coolant Tubes Prod. Liab. Litig. 2233 
Class-action 
Settlement 
Freda  
Wolfson105 
In re: Fosamax (Alendronate Sodium) Prod. 
Liab. Litig. (No. II) 2243 Ongoing 
James Edgar 
Kinkeade 
In re: DePuy Orthopaedics, Inc., Pinnacle Hip 
Implant Prod. Liab. Litig. 2244 Ongoing 
Rebecca  
R. Pallmeyer 
In re: Zimmer Nexgen Knee Implant Prod. 
Liab. Litig. 2272 
Aggregate 
Settlement 
J. Michelle 
Childs 
In re: Building Materials Corporation of 
America Asphalt Roofing Shingle Prod. Liab. 
Litig. 2283 
Class-action 
Settlement 
Gene  
E. K. Pratter 
In re: Imprelis Herbicide Marketing, Sales 
Practice, and Prod. Liab. Litig. 2284 
Class-action 
Settlement 
 
105. Formerly assigned to Joel A. Pisano.  
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Judge Litigation Name 
MDL 
Number Outcome 
Rebecca  
F. Doherty In re: Actos (Pioglitazone) Prod. Liab. Litig. 2299 
Aggregate 
Settlement 
Thomas  
B. Russell In re: Skechers Toning Shoe Prod. Liab.Litig. 2308 
Class-action 
Settlement 
Benita  
Y. Pearson 
In re: Ford Motor Co. Spark Plug and 3-Valve 
Engine Prod. Liab. Litig. 2316 
Class-action 
Settlement 
Joseph  
R. Goodwin 
In re: American Medical Systems Inc., Pelvic 
Repair System, Prod. Liab. Litig. 2325 
Aggregate 
Settlement 
Joseph  
R. Goodwin 
In re: Boston Scientific Corp Pelvic Repair Sys. 
Prods. Liab. Litig. 2326 
Aggregate 
Settlement 
Joseph  
R. Goodwin 
In re: Ethicon, Inc. Pelvic Repair Sys. Prods. 
Liab. Litig. 2327 
Aggregate 
Settlement 
William  
S. Duffey, Jr. 
In re: Wright Medical Technology, Inc., 
Conserve Hip Implant Prod. Liab. Litig. 2329 
Aggregate 
Settlement 
Brian  
M. Cogan106  In re: Propecia (Finasteride) Prod. Liab. Litig. 2331 Ongoing 
David  
C. Norton 
In re: MI Windows & Doors, Inc., Prod. Liab. 
Litig. 2333 
Class-action 
Settlement 
Cynthia  
M. Rufe 
In re: Zoloft (Sertraline Hydrochloride) Prod. 
Liab. Litig. 2342 
Defense 
Win 
Matthew  
F. Kennelley In re: Watson Fentanyl Patch Prod. Liab. Litig. 2372 
Aggregate 
Settlement 
David  
R. Herndon 
In re: Pradaxa (Dabigatran Etexilate) Prod. 
Liab. Litig. 2385 
Aggregate 
Settlement 
Joseph  
R. Goodwin 
In re: Coloplast Corp. Pelvic Support Sys. 
Prods. Liab. Litig. 2387 
Aggregate 
Settlement 
Robert  
L. Miller, Jr. 
In re: Biomet M2a Magnum Hip Implant 
Prod. Liab. Litig. 2391 
Aggregate 
Settlement 
Dale  
S. Fischer 
In re: Nexium (Esomeprazole) Products 
Liability Litigation 2404 
Defense 
Win 
Freda  
L. Wolfson 
In re: Plavix Marketing, Sales Practices & Prod. 
Liab. Litig. (No. II) 2418 Ongoing 
F. Dennis Saylor 
In re: New England Compounding Pharmacy, 
Inc. Prod. Liab. Litig. 2419 Bankruptcy 
Douglas 
P. Woodlock 
In re: Fresenius GranuFlo/NaturaLyte 
Dialysate Prod. Liab. Litig. 2428 
Aggregate 
Settlement 
 
106. Reassigned from John Gleeson. 
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Judge Litigation Name 
MDL 
Number Outcome 
Cathy Seibel In re: Mirena IUD Prod. Liab. Litig. 2434 
Defense 
Win 
Lawrence  
F. Stengel 
In re: Tylenol (Acetaminophen) Marketing, 
Sales Practices and Prod. Liab. Litig. 2436 
Aggregate 
Settlement 
 
